Source: Eli Lilly and Company, Phase 3 TRIUMPH clinical development program, 2025–2026; ClinicalTrials.gov records for Retatrutide / LY3437943.

Retatrutide – Dosage, Titration, and Administration in Clinical Trials

Published: May 13, 2026

Retatrutide is an investigational peptide agonist with simultaneous activity at GLP-1, GIP, and glucagon receptors. The molecule is being studied in extensive clinical programs related to obesity, overweight, and various metabolic disorders.

In clinical trials, particular attention is paid to the gradual increase of the studied dose. Instead of participants directly moving to the highest dose groups, protocols use sequential titration steps aimed at limiting the frequency and severity of adverse reactions.

Important: Retatrutide remains an investigational molecule, and currently, information on dosing regimens comes from controlled clinical trials. The values listed below describe research protocols and do not constitute a recommendation for individual use or treatment.

Why is Retatrutide dosage so important?

In the clinical development of Retatrutide, gradual titration is a crucial part of the trial design. The reason is related to the molecule's combined receptor activity and the need for the body to gradually adapt to the pharmacological effects.

Retatrutide simultaneously activates:

• GLP-1 receptors;
• GIP receptors;
• glucagon receptors.

These receptor systems are involved in regulating various physiological processes, including:

• appetite and satiety;
• food intake;
• gastrointestinal motility;
• energy expenditure;
• glucose and lipid metabolism.

In clinical trials, a faster increase in dose exposure is associated with a higher incidence of gastrointestinal adverse reactions, which is one of the reasons for using step-wise regimens.

How is Retatrutide administered in clinical trials?

In clinical programs, Retatrutide is studied as a subcutaneously administered molecule with a one-week interval between applications.

Participants in different dose groups undergo a predetermined titration period, with dose level increases occurring at intervals defined by the respective protocol.

The goals of this approach include:

• smoother adaptation to receptor activity;
• limiting gastrointestinal adverse reactions;
• better monitoring of individual tolerability;
• reducing discontinuations due to adverse reactions.

Titration Schedule

In part of the Phase 3 TRIUMPH program, sequential dose levels with gradual increases at defined intervals are used. The following table presents an example of a studied protocol:

These values describe a clinical research protocol. Different studies may use different target doses, starting levels, and titration periods.

Why do all participants start with 2 mg?

In early clinical phases, different starting dose levels were compared to evaluate the relationship between initial exposure, tolerability, and subsequent achievement of higher investigated doses.

A lower starting dose level tends to show better gastrointestinal tolerability during the initial stages of treatment within trials.

Among the assessed parameters are:

• frequency and severity of nausea;
• vomiting and diarrhea;
• discontinuation due to adverse reactions;
• ability to reach the predefined target dose level.

These observations contribute to the use of more gradual regimens in subsequent clinical programs.

What changes are observed at different stages?

2 mg

The lowest investigated starting level is used as a period for adaptation to the molecule's pharmacological activity.

Among the reported effects and reactions in clinical trials, the following may be observed:

• changes in appetite;
• earlier feeling of satiety;
• mild to moderate nausea in some participants.

4 mg

Upon moving to the next dose level, both metabolic effects and some of the gastrointestinal reactions may become more pronounced.

Studies report:

• nausea;
• constipation;
• diarrhea;
• post-meal discomfort.

6 mg

At intermediate dose levels, the body has already undergone several exposure stages, but some participants may experience new or temporarily intensified adverse reactions.

Reported reactions include:

• nausea;
• vomiting;
• changes in appetite;
• local reactions at the injection site.

9 mg

Higher dose levels represent the next step within the research protocols. It is around the periods of dose increase that some participants may experience more pronounced gastrointestinal symptoms.

12 mg

12 mg represents one of the high target dose levels investigated in clinical programs. After the titration period, some participants demonstrate better tolerability compared to the period immediately after dose increase.

Most common adverse reactions

The profile of the most commonly reported adverse reactions for Retatrutide is predominantly gastrointestinal and to some extent resembles those observed with other therapies affecting GLP-1 signaling.

Among the more frequently described reactions are:

• nausea;
• diarrhea;
• vomiting;
• constipation;
• decreased appetite;
• abdominal discomfort;
• local reactions at the injection site.

In clinical trials, a large proportion of these reactions are mild to moderate and are most commonly observed around periods of dose level increase.

What do the clinical data show?

Available clinical results show a clear relationship between dose exposure and the incidence of certain adverse reactions.

• gastrointestinal reactions are more frequent at higher dose levels;
• a significant portion of symptoms appear during titration periods;
• in some participants, tolerability improves after reaching a stable dose level;
• more gradual increases are used as a strategy to limit adverse reactions.

Long-term safety and the incidence of rarer adverse events continue to be evaluated within ongoing clinical programs.

Why is titration important?

The gradual increase in dose level has several main objectives in clinical trials:

• limiting gastrointestinal adverse reactions;
• smoother adaptation to combined receptor action;
• assessment of individual tolerability;
• monitoring of clinical and laboratory parameters during different stages;
• reducing the likelihood of participants discontinuing the trial due to adverse reactions.

Conclusion

Retatrutide is one of the actively investigated molecules in the field of obesity and metabolic diseases. Clinical programs show that gradual titration is an important part of how the molecule is evaluated in a controlled research environment.

Lower initial exposure and sequential progression to higher dose levels allow for better monitoring of tolerability and can limit the incidence of gastrointestinal adverse reactions during trials.

As the clinical development of Retatrutide continues, the final safety profile, optimal therapeutic strategies, and long-term outcomes are still being investigated.

Scientific Clarification

The material is prepared based on published scientific data and information from registered clinical trials. The presented dose values describe research protocols and do not constitute individual recommendations for dosing, treatment, or administration. Retatrutide is an investigational molecule whose safety and efficacy continue to be evaluated in controlled clinical studies.